Edesa Biotech, Inc. (NASDAQ:EDSA – Get Rating) major shareholder Der Velden Peter Van sold 145,129 shares of the business’s stock in a transaction that occurred on Monday, January 9th. The shares were sold at an average price of $2.66, for a total value of $386,043.14. Following the completion of the transaction, the insider now directly owns 163,170 shares in the company, valued at $434,032.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.
Edesa Biotech Price Performance
NASDAQ EDSA opened at $2.50 on Thursday. The company has a market cap of $48.38 million, a price-to-earnings ratio of -2.40 and a beta of 0.58. Edesa Biotech, Inc. has a 52 week low of $0.76 and a 52 week high of $5.98. The business has a 50 day moving average price of $1.31 and a 200-day moving average price of $1.48.
Edesa Biotech (NASDAQ:EDSA – Get Rating) last released its quarterly earnings data on Friday, December 16th. The company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.39. On average, equities research analysts anticipate that Edesa Biotech, Inc. will post -1.33 earnings per share for the current year.
Institutional Investors Weigh In On Edesa Biotech
Wall Street Analysts Forecast Growth
Separately, Brookline Capital Management reissued a “buy” rating on shares of Edesa Biotech in a research note on Monday, October 3rd.
About Edesa Biotech
Edesa Biotech, Inc, a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis.
- Get a free copy of the StockNews.com research report on Edesa Biotech (EDSA)
- Bloom Energy Powers Up After an Upgrade, is it Worth the Risk?
- Why Hershey Is a Sweet Recession Stock
- Will Amazon Stock Be Delivering for Investors in 2023?
- The Analysts Shift Trucking Sentiment Back into Forward
- The Institutions Book A Flight With Boeing
Receive News & Ratings for Edesa Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edesa Biotech and related companies with MarketBeat.com's FREE daily email newsletter.